18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02928861

Enrollment

100

Registered

2016-10-10

Start date

2016-10-31

Completion date

2018-12-31

Last updated

2016-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma, Large B-Cell, Diffuse

Keywords

Positron-Emission Tomography, Prognosis

Brief summary

The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of diffuse large B-cell lymphoma can predict disease progression

Detailed description

In this study investigators develop a prognostic model based on 18F-FDG PET/CT and test its ability for prognostic value in patients with DLBCL. PET/CT scans evaluation using the liver SUVmax as reference. Positive lesions in PET were indicated as SUVmax of residues higher than the threshold (1.6 fold of liver SUVmax) or new 18F-FDG avid lesions. 18F-FDG PET/CT-based prognostic model includes PET/CT image, dominant clinical and pathological prognostic factors to predicting disease progression during chemotherapy or survival in DLBCL.

Interventions

DEVICE18F-FDG PET/CT

18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post- injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. newly diagnosed DLBCL; 2. treated using an anthracycline-containing regimen with or without rituximab; 3. minimal follow-up at 6 months after the completion of first-line treatment; 4. complete medical history and clinicopathological data

Exclusion criteria

1. secondary malignant disease; 2. serious infection or inflammation (e.g., HIV); 3. primary central nervous system lymphoma; 4. hepatic or renal dysfunction.

Design outcomes

Primary

Measure	Time frame
2 year progression-free survival	up to 2 years after initial diagnosis

Countries

China

Contacts

Primary ContactXuejuan Wang, MD

xuejuan_wang@hotmail.com86 10-88196364

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026